- New alliance will crack down on adulterated products touting dietary supplement claims
- Three issues that will define 2011
- Moving PSE to Rx-only in Mo. lacks fiscal sense
- Walgreens encourages mail-order pharmacy patients to make the switch
- Walgreens' Pegus discusses evolving role of pharmacists at colloquium
WILMINGTON, Del. — A federal court has ruled in favor of AstraZeneca in a case regarding a cholesterol drug, the company said.
AstraZeneca said the Court of Appeals for the Federal Circuit upheld a decision by the U.S. District Court for the District of Delaware ruling that a patent covering the drug Crestor (rosuvastatin calcium) was valid and enforceable. The patent, which expires in 2016, covers the active ingredient of Crestor.
Under the court's decision, the Food and Drug Administration can't approve generic versions of the drug made by Apotex, Aurobindo, Cobalt, Mylan, Par, Sandoz, Teva, Sun and Torrent, but those companies may seek review by the Supreme Court.